EA029492B1 - Вакцина на основе микобактериальных антигенов - Google Patents

Вакцина на основе микобактериальных антигенов Download PDF

Info

Publication number
EA029492B1
EA029492B1 EA201590184A EA201590184A EA029492B1 EA 029492 B1 EA029492 B1 EA 029492B1 EA 201590184 A EA201590184 A EA 201590184A EA 201590184 A EA201590184 A EA 201590184A EA 029492 B1 EA029492 B1 EA 029492B1
Authority
EA
Eurasian Patent Office
Prior art keywords
antigens
agde
tng
vector
lei
Prior art date
Application number
EA201590184A
Other languages
English (en)
Russian (ru)
Other versions
EA201590184A1 (ru
Inventor
Эммануэль Тюпен
Ромен Миколь
Шарль Антуан Купе
Женевьев Иншопс
Мари Гуанвик
Натали Сильвестр
Жан-Батист Маршан
Сесиль Бени
Original Assignee
Трансген Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Трансген Са filed Critical Трансген Са
Publication of EA201590184A1 publication Critical patent/EA201590184A1/ru
Publication of EA029492B1 publication Critical patent/EA029492B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1289—Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EA201590184A 2012-07-10 2013-07-10 Вакцина на основе микобактериальных антигенов EA029492B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12305825 2012-07-10
EP12306539 2012-12-07
EP13305737 2013-06-03
PCT/EP2013/064624 WO2014009438A2 (en) 2012-07-10 2013-07-10 Mycobacterial antigen vaccine

Publications (2)

Publication Number Publication Date
EA201590184A1 EA201590184A1 (ru) 2015-06-30
EA029492B1 true EA029492B1 (ru) 2018-04-30

Family

ID=48782326

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590184A EA029492B1 (ru) 2012-07-10 2013-07-10 Вакцина на основе микобактериальных антигенов

Country Status (16)

Country Link
US (1) US10357555B2 (enExample)
EP (1) EP2872172B1 (enExample)
JP (1) JP6333814B2 (enExample)
KR (1) KR20150058152A (enExample)
CN (1) CN104640564B (enExample)
BR (1) BR112015000530A2 (enExample)
CA (1) CA2878800A1 (enExample)
EA (1) EA029492B1 (enExample)
IL (1) IL236650B (enExample)
MX (1) MX366206B (enExample)
MY (1) MY173004A (enExample)
SG (1) SG11201500171YA (enExample)
TW (1) TWI638829B (enExample)
UA (1) UA119228C2 (enExample)
WO (1) WO2014009438A2 (enExample)
ZA (1) ZA201500784B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201500171YA (en) * 2012-07-10 2015-02-27 Transgene Sa Mycobacterial antigen vaccine
EP3013364B1 (en) * 2013-06-25 2022-08-03 International AIDS Vaccine Initiative, Inc. Tuberculosis compositions and methods of using the same
EP3092000A1 (en) * 2014-01-09 2016-11-16 Transgene SA Fusion of heterooligomeric mycobacterial antigens
GB201400819D0 (en) 2014-01-17 2014-03-05 Sec Dep For Health The Mycobacterial antigen composition
WO2015126930A2 (en) * 2014-02-18 2015-08-27 Stc.Unm Booster drug therapy for mycobacterium infections
US10517943B2 (en) 2014-12-01 2019-12-31 Transgene S.A. Stable liquid vaccinia virus formulations
CA2975432A1 (en) 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
CN105601747B (zh) * 2015-10-21 2019-05-28 中山大学 一种结核杆菌融合蛋白及其在诱导外周血单个核细胞产生细胞因子的应用
KR101631054B1 (ko) * 2015-12-31 2016-06-16 중앙대학교 산학협력단 마이코박테리아 유래 CFP-10 또는 Ag85B에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편
CN105567660B (zh) * 2016-01-08 2018-11-20 中国人民解放军第四军医大学 一种大肠杆菌重组表达结核分枝杆菌Rv2837c活性蛋白的方法及其应用
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
EP3458088A2 (en) * 2016-05-21 2019-03-27 Infectious Disease Research Institute Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
US10428122B2 (en) * 2016-06-16 2019-10-01 International Aids Vaccine Initiative, Inc. Tuberculosis compositions and methods of treating or preventing tuberculosis
AU2017280065B2 (en) 2016-06-22 2021-07-01 International Aids Vaccine Initiative, Inc. Recombinant cytomegalovirus vectors as vaccines for tuberculosis
WO2018053294A1 (en) * 2016-09-16 2018-03-22 Infectious Disease Research Institute Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
CN106546737A (zh) * 2016-10-24 2017-03-29 广州迪澳医疗科技有限公司 一种体外检测活动性结核的方法
WO2018151930A1 (en) * 2017-02-17 2018-08-23 The Methodist Hospital Compositions and methods of determining a level of infection in a subject
CN107236023B (zh) * 2017-05-12 2021-05-07 苏州创澜生物科技有限公司 一种用于检测结核感染的抗原组合物及其应用
WO2019079155A1 (en) 2017-10-17 2019-04-25 International Aids Vaccine Initiative, Inc. CASSETTES OF ANTIGENS OF TUBERCULOSIS
CA3098015A1 (en) 2018-04-26 2019-10-31 Children's National Medical Center Mycobacterial antigen compositions and methods of use
CN109536431A (zh) * 2018-12-04 2019-03-29 江苏省农业科学院 复合生化复苏因子组合物及其应用
KR102135328B1 (ko) * 2018-12-19 2020-07-17 대한민국 결핵 2가 항원을 발현하는 약독화된 재조합 백시니아 바이러스 및 이를 포함하는 결핵 예방용 조성물
KR102157770B1 (ko) * 2019-01-11 2020-09-18 주식회사 파이지노믹스 가축의 결핵 진단을 위한 항원 펩타이드 조성물 및 이의 용도
CN109970183B (zh) * 2019-03-31 2021-01-15 浙江大学 一种复苏促进因子在印染废水处理中的应用及处理方法
WO2020249756A1 (en) * 2019-06-14 2020-12-17 Statens Serum Institut Fusion proteins for tuberculosis vaccines
CN110590958B (zh) * 2019-09-11 2021-04-13 中国人民解放军总医院第八医学中心 一种串联多肽及其在抗结核分枝杆菌的免疫保护中的应用
CN110590957B (zh) * 2019-09-11 2021-06-01 中国人民解放军总医院第八医学中心 一种融合蛋白及其在抗结核分枝杆菌的免疫保护中的应用
RU2724896C1 (ru) * 2019-11-14 2020-06-26 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Полиантигенная вакцина для профилактики и вспомогательного лечения туберкулеза
EP3842065A1 (en) * 2019-12-23 2021-06-30 Transgene Process for designing a recombinant poxvirus for a therapeutic vaccine
CN111443208B (zh) * 2020-03-23 2024-01-19 中国医学科学院北京协和医院 鉴别活动性结核病和潜伏性结核病的组合物
JP2023536844A (ja) * 2020-07-31 2023-08-30 コンバインド セラピューティクス インコーポレイテッド ワクチン接種を改善するための組成物および方法
KR20220059111A (ko) * 2020-11-02 2022-05-10 한양대학교 에리카산학협력단 결핵균의 Rv2626c 단백질에서 유래한 패혈증 치료용 펩타이드
US20250319173A1 (en) * 2021-03-12 2025-10-16 Institut Pasteur Lentiviral vectors targeting antigens to mhc-ii pathway and inducing protective cd8+ and cd4+ t-cell immunity in a host
CN116284283A (zh) * 2021-12-13 2023-06-23 江苏瑞科生物技术股份有限公司 重组结核分枝杆菌抗原、其制备方法和应用
KR102878370B1 (ko) * 2022-06-17 2025-10-31 주식회사 미코라파 면역활성 부위 융합 단백질을 포함하는 결핵 백신 조성물
MA71612A (fr) * 2022-07-29 2025-05-30 University Of Cape Town Constructions de vaccin comprenant des antigènes de tuberculose
IL318534A (en) * 2022-08-03 2025-03-01 BioNTech SE RNA for preventing or treating tuberculosis
WO2024027910A1 (en) * 2022-08-03 2024-02-08 BioNTech SE Rna for preventing or treating tuberculosis
CN116162141B (zh) * 2022-11-30 2024-04-12 中国疾病预防控制中心传染病预防控制所 一种结核分枝杆菌抗原epcra013及其应用
CN116041543B (zh) * 2022-12-07 2023-12-26 中国疾病预防控制中心传染病预防控制所 结核分枝杆菌多抗原融合蛋白及其编码基因和应用
CN116063418B (zh) * 2022-12-08 2024-04-12 中国疾病预防控制中心传染病预防控制所 结核分枝杆菌抗原组合物epdpa015及其制备方法与应用
CN117683141A (zh) * 2023-10-27 2024-03-12 中国疾病预防控制中心传染病预防控制所 结核分枝杆菌多抗原融合蛋白及编码基因和应用
WO2025092548A1 (zh) * 2023-11-03 2025-05-08 烟台派诺生物技术有限公司 一种用于预防结核分枝杆菌感染的纳米颗粒疫苗及其制备方法
CN118108815B (zh) * 2024-04-23 2024-07-23 成都康华生物制品股份有限公司 结核分枝杆菌多免疫原抗原、编码其的mRNA、应用
CN121627849A (zh) * 2024-08-14 2026-03-10 首都医科大学附属北京胸科医院 一种结核病mRNA疫苗及其制备方法与应用
CN121591855A (zh) * 2024-08-14 2026-03-03 首都医科大学附属北京胸科医院 一种结核病mRNA疫苗及其制备方法与应用
CN122097559A (zh) * 2024-11-29 2026-05-29 上海市重大传染病和生物安全研究院 一种结核分支杆菌保护性抗原组合及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006136162A2 (en) * 2005-06-23 2006-12-28 Statens Serum Institut Tuberculosis vaccines comprising antigens expressed during the latent infection phase
WO2009070700A1 (en) * 2007-11-27 2009-06-04 Aeras Global Tb Vaccine Foundation Recombinant bcg tuberculosis vaccine for eliciting immune responses to mycobacterium tuberculosis
WO2011144951A1 (en) * 2010-05-21 2011-11-24 Health Protection Agency Mycobacterial antigen composition
WO2012057904A1 (en) * 2010-10-27 2012-05-03 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
DE69633565T3 (de) 1995-06-15 2013-01-17 Crucell Holland B.V. Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
EP0988053A1 (en) 1997-06-11 2000-03-29 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US6204026B1 (en) * 1997-11-05 2001-03-20 The Board Of Trustees Of The University Of Arkansas Detection of M. tuberculosis complex via reverse transcriptase SDA
US6892139B2 (en) * 1999-01-29 2005-05-10 The Regents Of The University Of California Determining the functions and interactions of proteins by comparative analysis
CA2364934C (fr) 1999-02-22 2011-10-18 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
ATE519854T1 (de) 1999-05-17 2011-08-15 Crucell Holland Bv Rekombinantes adenovirus auf basis von serotyp 48 (ad48).
HU230198B1 (hu) 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
AU2002317940B9 (en) 2001-06-22 2008-06-05 The Secretary Of State For Health Mycobacterial antigens expressed under low oxygen tension
US7393540B2 (en) 2001-07-04 2008-07-01 Health Protection Agency Mycobacterial antigens expressed during latency
UA82466C2 (uk) 2001-07-18 2008-04-25 Бавариан Нордика А/С Спосіб посилення ампліфікації хордопоксвірусу
GB0125535D0 (en) 2001-10-24 2001-12-12 Microbiological Res Authority Mycobacterial genes down-regulated during latency
US7094412B2 (en) 2001-12-10 2006-08-22 Bavarian Nordic A/S Poxvirus containing formulations and process for preparing stable poxvirus containing compositions
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
WO2004006952A2 (en) 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines
US20040185555A1 (en) 2003-03-17 2004-09-23 Emini Emilio A. Adenovirus serotype 24 vectors, nucleic acids and virus produced thereby
EP1611237A1 (en) 2003-03-28 2006-01-04 Merck & Co., Inc. Adenovirus serotype 34 vectors, nucleic acids and virus produced thereby
JP4814800B2 (ja) 2004-01-23 2011-11-16 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー チンパンジーアデノウイルスワクチン担体
BRPI0518933A2 (pt) 2004-11-16 2008-12-16 Crucell Holland B V E Aeras Gl adenovÍrus recombinante defeituoso de replicaÇço, vetor de polinucleotÍdeo recombinante, vacina multivalente da tuberculose, e, uso do antÍgeno tb10.4 de mycobacterium
EA012436B1 (ru) 2005-01-05 2009-10-30 Айсис Инновейшн Лимитед Композиции для иммунизации против микобактерий
EA013016B1 (ru) 2005-03-31 2010-02-26 Лейден Юниверсити Медикал Сентер Способы и средства диагностики, профилактики и лечения инфекций mycobacterium и заболевания туберкулезом
EP1795540A1 (en) * 2005-11-30 2007-06-13 Imaxio Multimeric complexes of antigens and an adjuvant
CN100999550B (zh) * 2006-01-10 2010-10-06 中国人民解放军第三○九医院 结核分枝杆菌融合蛋白及其应用
US20100129403A1 (en) 2006-06-20 2010-05-27 Transgene S.A. Recombinant viral vaccine
EP2087128A4 (en) * 2006-11-01 2009-11-04 Immport Therapeutics Inc COMPOSITIONS AND METHODS FOR IMMUNOMINANT ANTIGENES
WO2008124647A2 (en) 2007-04-04 2008-10-16 Infectious Disease Research Institute Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof
CA2687304A1 (en) 2007-05-15 2008-11-20 Transgene S.A. Signaling peptides
BRPI0811787B1 (pt) 2007-07-03 2018-10-09 Transgene Sa usos de uma célula imortalizada e processo para imortalizar uma célula aviária
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
GB0722105D0 (en) * 2007-11-10 2007-12-19 Sec Dep For Environment Food A Antigens
US8361482B2 (en) * 2007-11-27 2013-01-29 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to mycobacterium tuberculosis in all physiological stages of infection and disease
GB0906215D0 (en) * 2009-04-09 2009-05-20 Lalvani Ajit Diagnostic test
SG176554A1 (en) 2009-05-12 2012-01-30 Transgene Sa Method for orthopoxvirus production and purification
ES2661215T3 (es) 2009-05-20 2018-03-28 Aeras Composiciones víricas; inmunógenas; secadas por pulverización; estables
GB0918154D0 (en) * 2009-10-16 2009-12-02 Isis Innovation Mycobacterial vaccines
WO2011159814A2 (en) * 2010-06-15 2011-12-22 The Regents Of The University Of California Novel live recombinant booster vaccine against tuberculosis
CA2808556A1 (en) * 2010-09-20 2012-03-29 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
ES2529442T3 (es) * 2010-09-28 2015-02-20 Abera Bioscience Ab Proteína de fusión para la expresión de proteínas secretoras
US20130115240A1 (en) * 2011-11-09 2013-05-09 National Health Research Institutes Recombinant bcg strains with enhanced ability to inhibit intracellular mycobacterial growth
SG11201500171YA (en) * 2012-07-10 2015-02-27 Transgene Sa Mycobacterial antigen vaccine
US20150211012A1 (en) * 2012-08-31 2015-07-30 Laboratorios Del Dr. Esteve S.A. Mycobacterium comprising expression vector with two auxotrophic selection markers and its use as vaccine
EP3013364B1 (en) * 2013-06-25 2022-08-03 International AIDS Vaccine Initiative, Inc. Tuberculosis compositions and methods of using the same
TWI654200B (zh) * 2013-08-30 2019-03-21 環球免疫公司 治療或預防結核病的組合物及方法
EP3092000A1 (en) * 2014-01-09 2016-11-16 Transgene SA Fusion of heterooligomeric mycobacterial antigens
GB201400819D0 (en) * 2014-01-17 2014-03-05 Sec Dep For Health The Mycobacterial antigen composition
WO2015161853A1 (en) * 2014-04-24 2015-10-29 Statens Serum Institut New m.tuberculosis vaccines
US10406219B2 (en) * 2014-09-09 2019-09-10 Virginia Tech Intellectual Properties, Inc. Multivalent Brucella vaccine for protection against mycobacterial infections and methods of using the same
US10428122B2 (en) * 2016-06-16 2019-10-01 International Aids Vaccine Initiative, Inc. Tuberculosis compositions and methods of treating or preventing tuberculosis
AU2017280065B2 (en) * 2016-06-22 2021-07-01 International Aids Vaccine Initiative, Inc. Recombinant cytomegalovirus vectors as vaccines for tuberculosis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006136162A2 (en) * 2005-06-23 2006-12-28 Statens Serum Institut Tuberculosis vaccines comprising antigens expressed during the latent infection phase
WO2009070700A1 (en) * 2007-11-27 2009-06-04 Aeras Global Tb Vaccine Foundation Recombinant bcg tuberculosis vaccine for eliciting immune responses to mycobacterium tuberculosis
WO2011144951A1 (en) * 2010-05-21 2011-11-24 Health Protection Agency Mycobacterial antigen composition
WO2012057904A1 (en) * 2010-10-27 2012-05-03 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANDERSEN, P.: "Vaccine strategies against latent tuberculosis infection", TRENDS IN MICROBIOLOGY., ELSEVIER SCIENCE LTD., KIDLINGTON., GB, vol. 15, no. 1, 17 January 2007 (2007-01-17), GB, pages 7 - 13, XP005823946, ISSN: 0966-842X, DOI: 10.1016/j.tim.2006.11.008 *
BALDWIN, S.L. ; BERTHOLET, S. ; KAHN, M. ; ZHARKIKH, I. ; IRETON, G.C. ; VEDVICK, T.S. ; REED, S.G. ; COLER, R.N.: "Intradermal immunization improves protective efficacy of a novel TB vaccine candidate", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 27, no. 23, 18 May 2009 (2009-05-18), AMSTERDAM, NL, pages 3063 - 3071, XP026058724, ISSN: 0264-410X, DOI: 10.1016/j.vaccine.2009.03.018 *
CHEN L, XU M, WANG Z Y, CHEN B W, DU W X, SU C, SHEN X B, ZHAO A H, DONG N, WANG Y J, WANG G Z: "The development and preliminary evaluation of a new Mycobacterium tuberculosis vaccine comprising Ag85b, HspX and CFP-10:ESAT-6 fusion protein with CpG DNA and aluminum hydroxide adjuvants", FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY., ELSEVIER SCIENCE B.V., AMSTERDAM., NL, vol. 59, no. 1, 1 June 2010 (2010-06-01), NL, pages 42 - 52, XP002713096, ISSN: 0928-8244, DOI: 10.1111/j.1574-695X.2010.00660.x *
HOUGHTON RAYMOND L ET AL: "Use of multiepitope polyproteins in serodiagnosis of active tuberculosis", CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY., AMERICAN SOCIETY FOR MICROBIOLOGY., US, vol. 9, no. 4, 1 July 2002 (2002-07-01), US, pages 883 - 891, XP002511611, ISSN: 1071-412X, DOI: 10.1128/CDLI.9.4.883-891.2002 *

Also Published As

Publication number Publication date
EP2872172B1 (en) 2018-11-14
TW201408691A (zh) 2014-03-01
IL236650A0 (en) 2015-02-26
EA201590184A1 (ru) 2015-06-30
UA119228C2 (uk) 2019-05-27
ZA201500784B (en) 2020-07-29
KR20150058152A (ko) 2015-05-28
HK1207962A1 (en) 2016-02-19
MY173004A (en) 2019-12-18
TWI638829B (zh) 2018-10-21
JP6333814B2 (ja) 2018-05-30
CN104640564A (zh) 2015-05-20
CA2878800A1 (en) 2014-01-16
BR112015000530A2 (pt) 2018-08-28
MX2015000449A (es) 2015-07-14
EP2872172A2 (en) 2015-05-20
WO2014009438A3 (en) 2014-04-10
US10357555B2 (en) 2019-07-23
SG11201500171YA (en) 2015-02-27
JP2015524794A (ja) 2015-08-27
CN104640564B (zh) 2020-08-04
WO2014009438A2 (en) 2014-01-16
US20150165014A1 (en) 2015-06-18
MX366206B (es) 2019-07-02
IL236650B (en) 2019-09-26

Similar Documents

Publication Publication Date Title
Shinnick The 65-kilodalton antigen of Mycobacterium tuberculosis
Kohsaka et al. Fine epitope mapping of the human SS-B/La protein. Identification of a distinct autoepitope homologous to a viral gag polyprotein.
TWI638829B (zh) 分枝桿菌抗原疫苗
WO2021163456A1 (en) T cell epitopes and related compositions useful in the prevention, diagnosis, and treatment of covid-19
US7132512B2 (en) Medicament for the treatment of chlamydial infection
Banerjee et al. Molecular cloning and expression of a recombinant Aspergillus fumigatus protein Asp f II with significant immunoglobulin E reactivity in allergic bronchopulmonary aspergillosis
EP2251693B1 (en) Method and kit for detection of anti-avibacterium paragallinarum antibody
US20140377740A1 (en) Soluble and membrane-anchored forms of lassa virus subunit proteins
Fantappie et al. Some Gram-negative lipoproteins keep their surface topology when transplanted from one species to another and deliver foreign polypeptides to the bacterial surface
JPH03504077A (ja) ライグラス花粉アレルゲン
CN114315989A (zh) 一种重组新型冠状病毒蛋白疫苗、其制备方法和应用
CN114478717B (zh) 一种重组新型冠状病毒蛋白疫苗、其制备方法和应用
Kato et al. Identification of a universal B cell epitope on DNA topoisomerase I, an autoantigen associated with scleroderma
US20110117134A1 (en) Gene library of Brucella suis surface antigens
AU772015B2 (en) Peptide fragments of cholera toxin B or enterotoxin B as vaccine adjuvants
US20160185835A1 (en) Immune system mediator
EP4144751A1 (en) New coronavirus vaccine and method for designing and obtaining a virus vaccine
US10117913B2 (en) Antigens of Pneumocystis murina and uses thereof
US20230167157A1 (en) ANTIGENIC DETERMINANTS PROTECTIVE IMMUNITY, SERODIAGNOSTIC AND MULTIVALENT SUBUNITS PRECISION VACCINE AGAINST SARS-CoV-2
CN113980942B (zh) 一种猪链球菌重组蛋白抗原Pul及其应用
KR101568457B1 (ko) ＧｒｏＥＬ을 포함하는 베체트병 진단용 키트
CN110759975B (zh) 一种多肽以及具有强adcc效应的抗体和应用
US8332159B2 (en) Method for enhancing efficacy of preparation of monoclonal antibody
Leuzzi et al. Genome mining and reverse vaccinology
HK40073048A (en) A recombinant protein-based covid-19 vaccine as well as its preparation method and application thereof

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU